OS of Ph+ ALL patients receiving TKIs. (A) OS at 10 years of patients enrolled in the UKALLXII/ECOG2993 trial, comparing cases receiving imatininb (imatinib cohort, n = 266) versus those not receiving it (pre-imatinib cohort, n = 175). Adapted from Fielding et al.¹¹  (B) OS at 5 years of patients receiving imatinib combined with de-intensified treatment (n = 135) versus those receiving imatinib plus intensive treatment (n = 133). Adapted from Chalandon et al.¹⁹